Share Prices & Company Research

Market News

01 Feb 2021 | 13:01

AstraZeneca to divest Viela Bio stake

(Sharecast News) - AstraZeneca has agreed to divest its 26.7% stake in US biotechnology company Viela Bio as part of the latter's proposed acquisition by Horizon Therapeutics. The London-listed pharmaceutical company said on Monday that it expects to receive cash proceeds and profit of around $760-$780m from the sale, which is due to complete by the end of the first quarter.

The divestment does not impact the group's financial guidance for 2020, AstraZeneca said.

Horizon Therapeutics announced earlier that it has agreed to buy Viela Bio for around $3.1bn.

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 14th May 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.